genOway SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0004053510
EUR
2.46
-0.01 (-0.4%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About genOway SA stock-summary
stock-summary
genOway SA
Pharmaceuticals & Biotechnology
Genoway SA is a France-based company that specializes in the provision of genetically modified mouse and rat models for biopharmaceutical companies, laboratories and research institutes. The Company offers a range of services, comprising site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). In addition, genOway SA's clients have access to its validated tool and consultancy services from a dedicated project manager. The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage. It has also formed partnerships with Charles River Laboratories, Altana Pharma, Dainihon Sumitomo Pharmceuticals and Euratools, among others.
Company Coordinates stock-summary
Company Details
Technopark 2, 31 Rue Saint Jean-de-Dieu , LYON None : 69007
stock-summary
Tel: 33 4 37654100
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Christian Grenier
Chairman of the Board
Mr. Olivier Costa de Beauregard
Director - Representative of Dassaut Developpement
Mr. Laurent Fraisse
Director
Mr. Robert Leon
Director - Representative of Finoway
Mr. Michel Lurquin
Director
Mr. Denis Soubeyran
Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 25 Million ()

stock-summary
P/E

22.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.12

stock-summary
Return on Equity

7.12%

stock-summary
Price to Book

1.41